The Ketamine Clinic Boom Is About to Meet the Same Federal Prosecutor Who Ended Florida’s Pill Mills

The typical ketamine infusion looks almost nothing like what its reputation as a party drug suggests: a recliner, a pulse oximeter clipped to a finger, forty-five minutes of a low-dose IV drip while a patient who has usually failed two or more antidepressants first drifts into a dissociative state and then, often, out of a depression that hadn’t lifted in years. That’s the legitimate core of the industry, and it’s real for a meaningful number of the people who walk into one of those clinics. It’s also, increasingly, not the part of the story regulators are focused on.

In St. Louis in 2024, federal prosecutors charged two physicians, Dr. Asim Ali and Dr. Mohd Malik, with conspiracy to unlawfully distribute controlled substances and healthcare fraud tied to their ketamine clinic operations. The indictment didn’t turn on whether ketamine helped anyone — it turned on operational details that sound almost mundane next to the drug itself: doctors who weren’t in the room when the drug was administered, and Medicare billing for evaluation visits that the government says didn’t happen the way they were billed. That’s the case that should worry every ketamine clinic operator in the country right now, and it’s a case almost nobody in recovery or treatment circles has heard of, because it isn’t about the drug. It’s about the paperwork around the drug — which, if you know how federal drug enforcement actually works, is exactly how these things usually start.

A decade of near-zero federal rulemaking built a $3.4 billion industry, and the bill for that is coming due through fraud statutes, not new drug law.

How a decade of nothing built a $3.4 billion industry

Ketamine has one FDA approval: as a surgical anesthetic, granted decades ago. Everything else — the infusion clinics for treatment-resistant depression, the at-home lozenges prescribed by telehealth startups, the ketamine-assisted psychotherapy practices — runs on off-label prescribing, a completely legal practice in which a physician prescribes an approved drug for a use the FDA hasn’t specifically evaluated, using their own clinical judgment. Off-label prescribing exists throughout medicine and is often exactly the right call. What’s unusual about ketamine is the scale: the clinic count grew from fewer than 100 in 2015 to more than 1,500 by 2024, and the U.S. market is now valued at roughly $3.4 billion, almost entirely built on a single off-label indication — depression — that the FDA has never been asked to formally evaluate for ketamine itself (only for esketamine, the FDA-approved nasal-spray cousin marketed as Spravato).

That gap between “legal” and “regulated” is where the industry actually lives. There is no ketamine-specific federal standard for how much clinical supervision a session requires, what screening a patient needs before treatment, or how many sessions constitute a reasonable course of care. State medical boards fill some of the gap, unevenly — a state-by-state legal tracker shows wildly different rules on who can prescribe, whether an in-person exam is required first, and how take-home lozenges are dispensed, meaning the same treatment can be tightly supervised in one state and essentially self-directed in the next. A regulatory review prepared for Wisconsin’s licensing board put it plainly: ketamine’s psychiatric use has expanded far faster than the professional and legal frameworks meant to govern it.

What’s forcing the reckoning now

Three separate pressures are converging on the industry at once. First, enforcement: the St. Louis indictment followed a 2023 DEA action that suspended a South Carolina telemedicine prescriber’s controlled-substance registration over large-scale prescribing without adequate exams — signals that federal attention is shifting from “is this legal” to “is this being billed and supervised honestly.” Second, the clock: the COVID-era telehealth waiver that lets prescribers issue controlled-substance prescriptions, including ketamine, without a prior in-person visit was scheduled to expire December 31, 2025, with a DEA extension proposed but not permanently settled — meaning a meaningful share of the industry’s patient-acquisition model has been operating under a countdown. Third, and easy to miss: the FDA’s newly finalized clinical-trial guidance for psychedelic drugs, published July 13, covers psilocybin, LSD, and MDMA — and pointedly does not cover ketamine, leaving it in a stranger position than before: surrounded on all sides by drugs now getting a formal federal rulebook, while it alone continues to operate on none.

None of this means ketamine stops working for the patients it’s genuinely helped. Treatment-resistant depression that hasn’t responded to anything else, including patients for whom ketamine or esketamine has been the first real relief in years, is a real and well-documented use case, and losing sight of that in a story about fraud and enforcement would be its own distortion. What the enforcement pattern actually targets is the growth-at-all-costs version of the business — clinics that scaled fast, skipped supervision, or billed for evaluation that didn’t happen — not the underlying medicine.

None of this means ketamine stops working for the patients it’s genuinely helped.

We’ve watched this exact movie before, with a different drug

If the shape of this story feels familiar, that’s because American medicine has run this experiment once already, with oxycodone instead of ketamine. In the mid-2000s, Florida became known as the “pill mill” capital of the country: more than 1,000 pain clinics operating with minimal oversight, and at one point 98 of the nation’s top 100 oxycodone-prescribing physicians practicing within the state. The response wasn’t a ban on oxycodone — it was House Bill 7095, signed by Governor Rick Scott on June 3, 2011, which tightened prescribing rules, required tracking of controlled-substance distribution, and funded dedicated law enforcement. Within about a year of enforcement, Florida’s presence on that top-100 list went from 98 physicians to zero. The drug didn’t change. The supervision around it did, fast, once regulators decided the boom had outrun the safeguards.

Ketamine clinics are not oxycodone pill mills — the harm profile, the patient population, and the clinical rationale are genuinely different, and it would be a mistake to import Florida’s opioid-era panic wholesale onto a depression-treatment industry with real evidence behind its core use case. But the structural pattern — explosive, lightly supervised growth in access to a controlled substance, followed by federal enforcement arriving through fraud and billing statutes rather than new drug scheduling — is close enough that it’s worth naming out loud, especially for the clinics operating in good faith who are about to get swept into scrutiny meant for the ones that weren’t.

If you’re currently in ketamine treatment, or considering it: the enforcement risk described here sits with clinics and billing practices, not with patients, and there’s no reason to interrupt care that’s working for you out of fear of a headline about fraud charges elsewhere. The one useful question worth asking your provider this week is a practical one — is a physician present during dosing, and what does aftercare and spacing between sessions look like — because those are precisely the operational details regulators are now scrutinizing, and a clinic that already has good answers is the one built to survive what’s coming.